View Post

NICE Approves Adjuvant Trastuzumab for HER2-positive Early Breast Cance

In Clinical Studies News by Barbara Jacoby

By: Dawn O’Shea   From: medscape.com The National Institute for Health and Care Excellence (NICE) has approved trastuzumab emtansine as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy. Trastuzumab is an adjuvant …